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Objectives. We sought to determine whether the C677T transi-
tion in the methylenetetrahydrofolate reductase (MTHFR) gene is
associated with increased risk for coronary artery disease (CAD)
or myocardial infarction (MI).
Background. Elevated plasma homocysteine has been identified
as a risk factor for coronary atherosclerosis. Homocysteinemia
may result from deficient MTHFR activity. A thermolabile form of
MTHFR, associated with a C677T genetic transition, shows
reduced activity and may be a risk factor for CAD.
Methods. Blood was withdrawn from patients undergoing cor-
onary angiography, and DNA was extracted by a phenol-
chloroform method. Genotyping was done by polymerase chain
reaction (PCR) amplification of a 198-base pair segment of the
MTHFR gene that brackets nucleotide 677. The amplicon was
digested with the HinfI restriction enzyme. Products were visual-
ized after electrophoresis in 1.5% agarose with ethidium bromide.
Results. Among 200 patients with a diagnosis of MI, the
polymorphic allelic frequency was 33.3%, compared with 32.1%
among 554 control subjects (p 5 0.68); homozygosity was present
in 11.5% of patients and 10.6% of control subjects (p 5 0.74, odds
ratio [OR] 1.09, 95% confidence interval [CI] 0.63 to 1.82).
Among 510 patients with severe CAD (>60% stenosis), allelic
frequency was 32.0%, compared with 34.8% for 168 subjects
without CAD (<10% stenosis, p 5 0.33); 11.2% of patients with
CAD compared with 13.1% of control subjects were homozygous
(p 5 0.50, OR 0.83, 95% CI 0.5 to 1.40).
Conclusions. Patients with angiographic evidence of CAD or
clinical MI do not show an increased frequency of the C677T
transition in the MTHFR gene. Our findings do not support this
polymorphism as a risk factor for CAD or MI in a predominantly
white, well nourished population of unrestricted age.
(J Am Coll Cardiol 1997;30:1206–11)
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Methylenetetrahydrofolate reductase (MTHFR) is an enzyme
that reduces 59,109-methylenetetrahydrofolate to 59-meth-
ylenetetrahydrofolate, the main circulating form of folate and
the methyl donor for the remethylation of homocysteine to
methionine. A thermolabile form of MTHFR has been iden-
tified (1,2) and found to be caused by a missense mutation in
its encoding gene, with the cytidine residue at nucleotide (nt)
position 677 being replaced by thymidine (C677T), resulting in
the substitution in the enzyme of a valine residue for alanine.
The homozygous (1/1) genotype of this mutation has been
found to specify a variant enzyme with reduced activity and to
be associated with elevated total plasma homocysteine (tHCY)
levels, particularly in the setting of low folate levels, as
compared with the wild type (2/2) and heterozygous (1/2)
genotypes (3–6).
It has been almost 30 years since hyperhomocysteinemia
has been recognized to accelerate atherosclerosis (7,8). More-
over, in the past few years, moderate, clinically common
elevations in tHCY levels have been associated with an in-
creased risk of vascular disease (9–19), including coronary
artery disease (CAD) (9,10) and myocardial infarction (MI)
(20,21). Elevations of tHCY might result from nutritional
deficiencies (including folate, pyridoxal phosphate [B6] and
methylcobalamin [B12] (5,20–23) or genetically determined
abnormalities of homocysteine metabolism (e.g., MTHFR), or
a combination of these.
These considerations have raised the possibility that the
relatively common C677T mutation in MTHFR might be an
important genetic risk factor for vascular disease through its
effects on homocysteine metabolism and tHCY (1–4,24). (A
potential link of the MTHFR variant with congenital neural
tube defects has also been proposed [25].) Recently, Kluijt-
mans et al. (24) reported a threefold increase in the relative
risk of premature vascular disease in homozygous individuals
in a small case-control study. We therefore undertook a larger
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(n 5 754), prospective study of the MTHFR polymorphism in
a population defined by coronary angiography to test the
hypothesis that the homozygous variant genotype is associated
with an increased risk of MI and CAD.
Methods
Study hypotheses. We postulated that the (1/1) mutant
homozygote would be associated with an increased risk (odds
ratio [OR] $1.5) for MI and CAD in patients studied by
coronary angiography (recessive model). Second, we assessed
whether the polymorphic C677T transition allele in the
MTHFR gene would be associated with these diseases (dom-
inant model).
Patients. The study sample consisted of patients undergo-
ing coronary angiography because of either symptoms of
suspected CAD or unrelated conditions requiring angio-
graphic evaluation (e.g., valvular disease, cardiomyopathy).
Patients were of unrestricted age and gender and gave written,
informed consent for a blood draw at the time of angiography
for use in confidential “deoxyribonucleic (DNA) bank” studies
approved by the hospital’s Institutional Review Board. Sub-
jects were residents of Utah, southwestern Idaho or southeast-
ern Wyoming, a population that is ethnically primarily of
Northern European (Anglo-Scandinavian) descent and genet-
ically representative of U.S. Caucasians (26).
Key demographic characteristics were captured on comput-
erized angiographic data forms, including age, gender and
history of MI. Assessment of CAD was determined by a review
of angiograms by the patient’s cardiologist and entered into the
computer data base in a format modified after the CASS
protocol (27,28). Patients were designated as having CAD if
they had .60% stenosis of at least one coronary artery or its
major branch and having no CAD if ,10% stenosis was
present in all major vessels. Patients with mild CAD (10% to
60% stenosis) were given an “indeterminate” CAD status.
Final designations of MI and CAD status were made after
considering arteriographic and ventriculographic results to-
gether with patient history, without knowledge of DNA geno-
type. Coronary angiograms were read without knowledge of
genotypic results.
DNA extraction. Blood (20 to 30 ml) was withdrawn and
collected in EDTA at the time of angiography. The leukocyte
buffy coat was recovered by centrifugation, washed in TNE
buffer (10 mmol/liter Tris base, 10 mmol/liter sodium chloride,
1 mmol/liter EDTA), resuspended in 3 ml of a solution of
sodium chloride (75 mmol/liter) and EDTA (24 mmol/liter)
containing 250 ml of proteinase K (4 mg/ml) and 125 ml of 20%
sodium dodecyl sulfate and incubated at 65°C overnight. The
mixture then was combined with 0.5 vol equilibrated phenol
and 0.5 vol chloroform:isoamyl alcohol (24:1), placed on a
shaker for 1 h and then centrifuged at 1,000 g for 10 min. The
upper phase was removed, reextracted with 1 vol chloroform
and centrifuged. The upper phase was collected and mixed
with 0.1 vol 3 mol/liter sodium acetate (pH 5.2), shaken and
combined with 2 vol cold isopropanol. Precipitated DNA was
removed with a glass hook and resuspended in Tris/EDTA
buffer (0.01 mol/liter Tris, 0.001 mol/liter EDTA, pH 8.0).
DNA genotyping. Identification of the C to T transition at
nt677 was done using the method of Frosst et al. (4). Previously
published primers were used to amplify a 198-base pair (bp)
segment containing nt677. The primers were (59-39)TGA-
AGGAGAAGGTGTCTGCGGGA and AGGACGGTGCG-
GTGAGAGTG. The amplification protocol consisted of an
initial denaturation segment at 94°C for 5 min. After this, each
cycle consisted of three segments (93°C for 50 s, 55°C for 50 s
and 72°C for 30 s). The cycle was repeated 30 times, followed
by an additional extension at 72°C for 5 min. The 198-bp
product was treated with 5 U HinfI restriction endonuclease (3
to 4 h at 37°C), which recognizes a novel restriction site created
by the C to T transition at nt677. The amplified product from
the mutant gene was cleaved into 175-bp and 23-bp fragments
by HinfI, which leaves the wild-type gene unaffected. After
electrophoresis through 1.5% agarose gel, the digestion prod-
ucts were visualized by staining with 1 mg/ml of ethidium
bromide. The gels were read without knowledge of the clinical
and angiographic results by a single experienced reader. A
representative gel is shown in Figure 1.
Meta-analysis. A meta-analysis was performed as previ-
ously described (29), combining the present study with three
recently published reports (30–32) examining the MTHFR
C677T transition and risk of MI. Briefly, the meta-analysis
consists of tests for association and homogeneity. Homogene-
ity testing assesses the reproducibility (homogeneity) of the
different ORs determined in the respective studies. The overall
test for association then assesses the significance of the asso-
ciation between the C677T mutation and MI for all studies
combined.
Statistical planning and analysis. Power calculations indi-
cated that to determine an OR of $1.5 for MI or CAD of the
C677T transition polymorphism in the MTHFR gene with a
power of 80% at an alpha level of 0.05 in a population with an
incidence of the T allele of 35% (30,31), a sample size of ;375
subjects per group is required (GB-STAT for Windows).
Accordingly, we assembled and studied a group of 754 sub-
jects; 70% of the group had severe CAD and 28% had a history
of MI.
Allelic and genotypic frequencies were determined from
observed genotype counts, and the expectations of the Hardy-
Abbreviations and Acronyms
bp 5 base pair
CAD 5 coronary artery disease
CI 5 confidence interval
DNA 5 deoxyribonucleic acid
EDTA 5 ethylenediaminetetraacetic acid
tHCY 5 total plasma homocysteine (level)
MI 5 myocardial infarction
MTHFR 5 methylenetetrahydrofolate reductase
nt 5 nucleotide
OR 5 odds ratio
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Weinberg equilibrium were evaluated by chi-square analysis.
Comparisons between genotypic frequencies were done using
chi-square analysis; ORs with 95% confidence intervals (CIs)
were calculated as previously described (29).
Results
Patient groups. A total of 754 subjects were studied (aver-
age age 64 years, range 17 to 89); 200 had a history of MI and
510 had significant CAD. Key patient characteristics are
summarized by disease subgroup in Table 1. As might be
expected, those with CAD were older and more frequently
men, smokers and diabetics. Those with MI were more fre-
quently men and smokers. Blood pressure declined slightly
after MI.
Genotypic and allelic frequencies. Genotypic and allelic
frequencies for the study groups are shown in Table 2. The
C677T (1) allelic frequency in control subjects without MI was
32.1%. Their genotypic frequencies were in agreement with
those predicted by the Hardy-Weinberg equilibrium. These
allelic and genotypic frequencies are also similar to those
previously reported for U.S. physicians (31) and in a Boston
area study (30).
The C677T (1) allelic frequency in the control group
without CAD was 34.8%. The genotypic frequencies in this
control group were also in agreement with the frequencies
predicted by the Hardy-Weinberg equilibrium.
Figure 1. Example of MTHFR genotyping using polyacrylamide gel
electrophoresis of PCR amplification products.
Table 1. Characteristics of Patients With Myocardial Infarction or Coronary Artery Disease and
Control Patients
MI CAD
Patients
(n 5 200)
Control Subjects
(n 5 554)
Patients
(n 5 510)
Control Subjects
(n 5 168)
Age (yr) 63 6 12 65 6 11 65 6 10* 62 6 12
Range 31–89 17–89 36–89 17–84
Male 79† 67 79* 48
SBP (mm Hg) 132 6 22* 141 6 24 138 6 24 139 6 23
DBP (mm Hg) 71 6 9‡ 73 6 11 72 6 10 73 6 12
Smoker 34† 23 27‡ 18
Diabetes 16 16 18‡ 11
Cholesterol (mg/dl) 204 6 43 207 6 52 207 6 47 203 6 59
(n 5 155) (n 5 371) (n 5 382) (n 5 100)
Hypercholesterolemia 31 36 35 33
(% $220 mg/dl) (n 5 155) (n 5 371) (n 5 382) (n 5 100)
*p # 0.0001, †p #0.01, and ‡p # 0.05 versus control subjects. Data presented are mean value 6 SD, range or percent
of patients. Mean values are based on nearly complete data, except for cholesterol. CAD 5 coronary artery disease;
DBP 5 diastolic blood pressure; SBP 5 systolic blood pressure.
Table 2. Genotypic and Allelic Frequencies in Patients With
Myocardial Infarction or Coronary Artery Disease and
Control Subjects
(1/1) (1/2) (2/2)
1 (T)
Allele
MI (n 5 200) 11.5 (23) 43.5 (87) 45.0 (90) 33.3 (133)
No MI (n 5 554) 10.6 (59) 43.0 (238) 46.4 (257) 32.1 (356)
CAD (n 5 510) 11.2 (57) 41.6 (212) 47.3 (241) 32.0 (326)
No CAD (n 5 168) 13.1 (22) 43.5 (73) 43.5 (73) 34.8 (117)
Data presented are percent (number) of patients. (1/1) 5 homozygous;
(1/2) 5 heterozygous; (2/2) 5 wild-type; 1(T) 5 C677T (1) allele; other
abbreviations as in Table 1.
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Association between MTHFR polymorphism and MI.
Among the 200 patients with a diagnosis of MI, the mutant
C677T allelic frequency was 33.3%, compared with 32.1%
among 554 control subjects (p 5 0.68) (Table 2). The distri-
bution of the genotypes was within the expectation of the
Hardy-Weinberg equilibrium. Homozygosity for the (1/1)
genotype among patients and control subjects was 11.5% and
10.6%, respectively (p 5 0.74). The OR for MI was 1.09 (95%
CI 0.63 to 1.82) for the (1/1) versus non(1/1) genotypes.
Association between MTHFR polymorphism and CAD.
Among the 510 patients with severe CAD (.60% stenosis),
the mutant C677T (1) allelic frequency was 32.0%, compared
with 34.8% for 168 subjects without CAD (,10% stenosis)
(p 5 0.33); 11.2% of patients with CAD compared with 13.1%
of control subjects were homozygous for the mutation (p 5
0.50). The OR for CAD was 0.83 (95% CI 0.49 to 1.40) for the
(1/1) versus non(1/1) genotypes. The distribution of the
genotypes was within the expectation of the Hardy-Weinberg
equilibrium.
Association of MTHFR polymorphism with MI or CAD by
age and other prespecified characteristics. The MTHFR poly-
morphism might affect risk primarily in a certain age group
(i.e., younger patients). Thus, genotypic associations with
disease were separately assessed by age (Table 3). For subjects
,60 years of age, the OR for MI was 1.35 (95% CI 0.58 to
3.12) for the (1/1) versus non(1/1) genotypes, whereas it was
0.95 (95% CI 0.49 to 1.83) for those $60 years old. The OR of
CAD was 1.40 (95% CI 0.56 to 3.50) for the (1/1) versus
non(1/1) genotypes for subjects ,60 years old, and it was 0.65
(95% CI 0.34 to 1.24) for those $60 years old. The possibility
of associations between the MTHFR polymorphism and MI in
other prespecified subgroups defined by baseline characteris-
tics was also explored (Table 3), but no noteworthy trends were
found.
Discussion
Summary of study results. In our moderately large (n 5
750), prospectively studied, angiographically defined sample
group, we found no relation between the MTHFR C677T
polymorphism and the risk of either MI (OR 1.09, p 5 0.7) or
angiographically defined CAD (OR 0.83, p 5 0.5). Thus, in a
generally well nourished, predominantly white, middle class
population, this mutation does not appear to be a useful
Table 3. Relative Risk of Nonfatal Myocardial Infarction of (1/1) and Non(1/1) Genotypes in
Prespecified Subgroups
Characteristic (1/1) Non(1/1) OR (95% CI) p Value
Age ,60 yr
MI1 10 61 1.35 0.48
MI2 17 140 (0.58–3.12)
Age $60 yr
MI1 13 116 0.95 0.87
MI2 42 355 (0.49–1.83)
Hypertension
MI1 11 92 1.00 1.00
MI2 28 234 (0.48–2.09)
No hypertension
MI1 12 85 1.19 0.63
MI2 31 261 (0.58–2.42)
Cholesterol $220 mg/dl
MI1 5 43 0.74 0.58
MI2 18 115 (0.26–2.12)
Cholesterol ,220 mg/dl
MI1 15 92 1.22
MI2 28 210 (0.62–2.39)
Smoker
MI1 9 58 1.14 0.77
MI2 15 110 (0.47–2.76)
Nonsmoker
MI1 14 119 1.03 0.93
MI2 44 385 (0.55–1.94)
Diabetes
MI1 5 26 1.03 0.96
MI2 14 75 (0.34–3.14)
No Diabetes
MI1 18 151 1.11 0.72
MI2 45 420 (0.62–1.98)
Data presented are number of patients. CI 5 confidence interval; MI 5 myocardial infarction; OR 5 odds ratio;
other abbreviations as in Table 2.
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marker of increased cardiovascular risk. Although differences
were not significant, a trend was noted for the (1/1) genotype
with MI and CAD risk in younger patients that may deserve
further exploration in larger studies with greater power, espe-
cially in patients with relative folate deficiency.
Comparison with recent published reports. Our results do
not confirm those of the small case-control study of Kluijtmans
et al. (24), who reported a threefold increase in the relative risk
of premature vascular disease in homozygous subjects, but are
in keeping with three larger, more recent reports. In a Boston
area health study report (30), MTHFR genotypic frequencies
were similar for 190 patients with MI and 188 control subjects:
15.3% were homozygous for the variant polymorphism among
patients compared with 14.4% among control subjects (relative
risk 1.1, 95% CI 0.6 to 1.9). Stratification by folate intake did
not alter the results. Plasma tHCY and folate levels were
minimally higher and folate levels minimally lower among
patients compared with control subjects, and levels did not
differ significantly by genotype.
In a health study report of U.S. physicians (31), the
frequency distribution of the MTHFR polymorphism was
similar among patients and control subjects: the (1/1) geno-
type was present in 11% who developed MI (n 5 293) and 13%
who did not (n 5 290) (relative risk 0.84, p 5 NS). In an
exploratory analysis, the relative risk of MI in younger men
(,60 years old) with low folate levels was 1.7 (95% CI 0.7 to
4.5) for the (1/1) genotype and 2.4 (95% CI 0.9 to 6.4) for the
combined genotypes (1/2) and (1/1), each of which was
compared with high folate and the wild type genotype (2/2) as
reference. Neither comparison was significant. The study did
confirm an association between the MTHFR polymorphism
and tHCY levels, however, which averaged 12.6 6 0.5 nmol/ml
in (1/1) and 10.6 6 0.3 in (2/2) subjects (p , 0.01). The
difference was most marked among men with folate levels in
the lowest quartile of the distribution of control subjects:
16.0 6 1.1 versus 12.3 6 0.6 nmol/ml, respectively (p , 0.001).
Van Bockxmeer et al. (32) screened 555 whites with angio-
graphic evidence of CAD and 143 community control subjects;
212 were categorized as to previous MI status. Homozygosity
for the mutant C677T allele was found in 10.5% of control
subjects, 10.6% of patients with CAD (,50 years old) and
9.1% of those with previous balloon angioplasty evaluated for
restenosis. No relation was found between MI, CAD or
restenosis and genotype. Plasma folate distributions were
similar in control subjects and patients (32).
Overview of studies. If this and the three other major
prospective studies (30–32) are combined (Fig. 2), a relatively
large experience with almost 2,000 patients and control sub-
jects is obtained. The studies are consistent in showing no
overall association between the MTHFR polymorphism and
MI risk. The combined OR was 0.98 (95% CI 0.73 to 1.30).
Except for the initial, small report that provoked further
studies (24), these published observations are consistent in
showing no evidence for an influence of the polymorphism on
MI risk (or on angiographic CAD) in well nourished, mostly
Caucasian populations.
Pathophysiologic considerations. Why is there an absence
of an effect of the polymorphism on MI risk when studies as a
whole are consistent with an effect on tHCY levels, especially
among those with lower folate intake? It appears likely that
any effect of the genetic defect is indirect and acts through
effects on tHCY levels. However, these effects may be of
limited magnitude (mild or insignificant clinical impact), ex-
cept in specific, vulnerable groups, such as young individuals
with very low folate levels (31). Overall, among well nourished
subjects, the genetic defect may be largely compensated for by
adequate dietary folate intake. We did not have plasma
samples available for folate and tHCY measurements, but in
the other recent studies (30–32), they were measured in
subsets of subjects, and the findings were consistent in showing
little if any overall effect of the polymorphism on folate and
tHCY levels. However, the results of these four moderately
large studies in groups with favorable socioeconomic and
nutritional status do not exclude the possibility of an effect in
a younger sample group with substantially lower folate intake
(31). Thus, additional studies in such groups should be encour-
aged.
Conclusions. In a prospectively studied, angiographically
defined U.S. population of European descent, no relation of
the MTHFR C677T mutation with the risk of either MI or
angiographically defined CAD was found. This finding for MI
is in contrast to molecular pathophysiologic considerations and
an initial, small clinical study (24), but is consistent with three
contemporary studies of moderate size (30–32). We also
observed an absence of an effect of genotype on angiographi-
cally defined CAD. These findings suggest that this mutation is
not likely to be a useful marker of increased cardiovascular risk
in this or similar groups. An effect of the polymorphism in
younger subjects with substantially lower folate intake is still
possible and should be explored in future studies.
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